beau darley Chemotherapy drug Taxotere lawsuits skyrocketing over permanent hair lossHair loss is something cancer patients have come to expect as a side effect of chemotherapy. The hair usually grows back after the treatments end and the body starts to heal. Unfortunately, many cancer patients who took the chemotherapy drug Taxotere are now experiencing permanent hair loss.

A growing number of the patients have filed suit against French drugmaker Sanofi Aventis, Taxotere’s manufacturer. The U.S. Judicial Panel on Multidistrict Litigation (JPML) reports that the number of lawsuits has more than tripled since the end of last year – growing from 267 in mid-December to 949 in mid-April. Last October the JPML established a multidistrict litigation (MDL) for permanent hair loss claims in the U.S. District Court of the Eastern District for Louisiana.

Taxotere is two times as potent as its safer alternative, Taxol. Bristol-Meyers Squibb manufactures Taxol and despite Sanofi’s previous marketing claims, the two drugs have the same efficacy, according to the Jere Beasley Report. However, unlike Taxotere, Taxol does not destroy hair follicles, allowing the hair to regrow.

Permanent hair loss is more than cosmetic. Many cancer patients see it as an unnecessary side effect that serves as a constant reminder of their struggle.

The Food and Drug Administration (FDA) approved Taxotere in 1997. Righting Injustice explains that Sanofi knew about the potential side effect and warned patients outside of the U.S. beginning in 2005. However, it did not caution U.S. consumers until 2015 and only after the FDA demanded the manufacturer update the label with a warning.

* * *

Lawyers at Beasley Allen are currently investigating potential cases involving individuals who have suffered permanent hair loss following chemotherapy with Taxotere. For more information on this subject, contact Beau Darley or Melissa Prickett, lawyers in our firm’s Mass Torts Section, at 800-898-2034 or by email at Beau.Darley@beasleyallen.com or Melissa.Prickett@beasleyallen.com.

Sources:
U.S. Judicial Panel on Multidistrict Litigation
Jere Beasley Report (November 2016)
Righting Injustice



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Taxotere may add misery of permanent hair loss to...

Some breast cancer survivors have also been left with an enduring, physical reminder of their battle –...

Taxotere MDL trial dates set

Taxotere, a chemotherapy drug approved by the Food and Drug Administration (FDA) to treat breast cancer...

Rare ruling in Taxotere MDL allows claims against...

A recent, rare ruling by the U.S. Judicial Panel on Multidistrict Litigation (JPML) allows claims...

Opioid overdoses decrease American life expectancy for...

It’s been called an epidemic and a national health emergency, and it has probably affected someone you...

More than 6,000 lawsuits pending in MDL against...

The U.S. Judicial Panel on Multidistrict Litigation reports that there are now 6,121 lawsuits in a...
Risperdal Side Effects

Risperdal plaintiff granted retrial against J&J,...

Like thousands of other plaintiffs, W.C. alleges the defendants didn’t adequately warn about the risk...

Wonderful to work with

Beasley Allen did a great job with my case. They were wonderful to work with. They were available by phone when I needed them, treated me with the utmost respect and worked hard on my behalf. If a need arises in the future, I would definitely call on them again.

—Geraldine